US Midday Movers: CGON Surges 12% While SMMT Tumbles 15%

CG Oncology (CGON) rose 12.36% to $83.59, H World (HTHT) +10.24% to $55.55, Telus (TU) +9.62% to $9.35, Molina (MOH) +9.16% to $228.68, Powell (POWL) +7.12% to $152.88. Summit (SMMT) fell 15.51% to $11.96, Gunnison (GUNN) -14.41% to $6.59, GDS (GDS) -13.76% to $17.09, RUM (RUM) -12.91% to $5.03, Strive (ASST) -10.44% to $19.13.

Original reporting
Published Nov 16, 2026, 5:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 6:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
US Midday Movers: CGON Surges 12% While SMMT Tumbles 15% — source image
Decision brief

The 30-second read

$CGONBullishLow
01

Why it matters

The main tradable signal is intraday momentum and sector rotation, but the article does not provide the underlying cause for any single name’s move.

02

Market read

Useful for identifying which names are experiencing extreme intraday moves, but not sufficient to infer new fundamental information.

03

What to watch

Without disclosed catalysts (earnings, trial results, guidance, regulatory actions, commodity moves), traders should treat this as a momentum/flow snapshot and verify whether any underlying filings or sector news hit the tape the same day.

Relevance 4/10Novelty 2/10Timing: midday session on Monday, 16 Nov 2026

Background

This is a midday US market wrap listing top gainers and losers with large percentage moves across multiple sectors.

Company-level read

Ticker impact

$CGONBullishMedium confidence
Context

CG Oncology shares surged 12.36% at midday, with the article attributing the move to strong buying interest in the oncology specialist.

Expected impact

Likely continued volatility and potential mean reversion after a sharp midday gain.

Evidence & confidence

The piece provides only the price move and a generic demand explanation, with no new company-specific disclosure beyond the move itself.

$HTHTBullishLow confidence
Context

H World Group Limited rose 10.24% at midday, described as attracting strong buying interest.

Expected impact

Likely further intraday strength or choppy consolidation as the market digests the move.

Evidence & confidence

The article does not specify what drove the rally beyond broad 'buying interest' framing.

$TUBullishLow confidence
Context

Telus Corporation gained 9.62% at midday, cited as part of the broader healthcare and hospitality-led gainers.

Expected impact

Near-term upside pressure may fade if the move was primarily sector/tape related.

Evidence & confidence

No TU-specific catalyst, filing, or guidance is disclosed.

$MOHBullishLow confidence
Context

Molina Healthcare rallied 9.16% at midday, with the article grouping it among the top gainers.

Expected impact

Potential continuation early, but higher risk of pullback as midday extremes normalize.

Evidence & confidence

The article provides price action only, not a new MOH disclosure.

$POWLBullishLow confidence
Context

Powell Industries rose 7.12% at midday, listed among the top five gainers.

Expected impact

Likely choppy trading with mean-reversion risk after a midday jump.

Evidence & confidence

No concrete POWL catalyst is included beyond the move.

$SMMTBearishLow confidence
Context

Summit Therapeutics shares fell 15.51% at midday, the steepest decline in the article’s list.

Expected impact

Further downside volatility possible if sellers remain in control, with potential oversold bounce risk.

Evidence & confidence

The piece lacks any disclosed SMMT-specific catalyst such as trial data, guidance, or regulatory action.

$GUNNBearishLow confidence
Context

Gunnison Copper dropped 14.41% at midday, cited as part of the broader selling pressure in mining stocks.

Expected impact

Downward pressure may persist if broader mining sentiment stays weak.

Evidence & confidence

No copper-price linkage or GUNN-specific event is provided.

$GDSBearishLow confidence
Context

GDS Holdings fell 13.76% at midday, included among the biggest decliners.

Expected impact

Potential for continued volatility, but direction may depend on broader sector flows.

Evidence & confidence

The article does not mention any GDS-specific news driver.

Market effects

The article frames outsized moves by sector (healthcare and hospitality up, biotech and mining down), suggesting intraday factor rotation rather than idiosyncratic fundamentals.

US equities tape shows divergent leadership, but no cross-asset driver is specified.

No explicit global macro or cross-market catalyst is provided.

Counterpoint

Because the piece provides only price moves and generic 'buying interest'/'selling pressure' language, the moves may be largely mechanical (flows, liquidity, index/ETF rebalancing) rather than information-driven.

Key entities

  • CG Oncology, Inc.

    Oncology specialist whose shares jumped 12.36% at midday.

  • Summit Therapeutics Inc.

    Biotech name whose shares fell 15.51% at midday.

Related articles

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$TUMedAI 8/10

What you need to know about a proposed Quebecor-Telus merger

Quebecor Inc. proposed a $31-billion merger with Telus, raising concerns about competition and regulatory approval. Analysts suggest the deal could reduce wireless competition, potentially increasing prices. Telus's stock has declined 32% year-to-date, making it an attractive target. The merger could face regulatory hurdles, including potential asset spin-offs.

$POWLHighAI 8/10

Powell Industries beats estimates on strong order growth

Powell Industries (POWL) reported Q4 adjusted EPS of $2.23, beating estimates by $0.67, with revenue of $397M, up 33% YoY. Growth was driven by Commercial, Oil & Gas, and Electric Utility markets. New orders reached $710M, including large LNG and data center deals. FY2026 revenue was $1.3B, up 14%, with net income of $221M, up 22%. Shares rose 0.8% in after-hours trading.

$POWLMedAI 8/10

Powell Industries: Fiscal Q4 Earnings Snapshot

Powell Industries (POWL) reported fiscal Q4 earnings of $81.5M, or $2.23 per share, beating analyst estimates of $1.52 per share. Revenue was $396.7M, also surpassing expectations of $328.4M. Annual profit was $221M, or $6.04 per share, on revenue of $1.26B.

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.